Association with clinicopathological data and the expression of MUC5B of patients with EGFR-mutant NSCLC
| Parameters | MUC5B | p Value | ||
|---|---|---|---|---|
| Total | Negative (−) | Positive (+) | ||
| (n=78) | (n=51) | (n=27) | ||
| Median age (range, years) | 66.9 (41–85) | 66.7 (42–83) | 67.3 (41–85) | 0.674 |
| Gender | ||||
| Male | 35 (45%) | 22 (28%) | 13 (17%) | |
| Female | 43 (55%) | 29 (37%) | 14 (18%) | 0.6721 |
| Smoking status | ||||
| Non-smoker | 42 (54%) | 28 (36%) | 14 (18%) | |
| Smoker | 36 (46%) | 23 (29%) | 13 (17%) | 0.7971 |
| Histological type | ||||
| Adenocarcinoma: bronchoalveolar | 27 (35%) | 16 (21%) | 11 (14%) | |
| Adenocarcinoma | 43 (55%) | 29 (37%) | 14 (18%) | |
| Squamous cell carcinoma | 8 (10%) | 6 (8%) | 2 (3%) | 0.6522 |
| Median tumour size (range, mm) | 25.7 (8–60) | 26.1 (8–60) | 24.9 (8–50) | 0.8771 |
| Degree of differentiation | ||||
| Well | 35 (45%) | 22 (28%) | 13 (17%) | |
| Moderately | 28 (36%) | 19 (24%) | 9 (12%) | |
| Poorly | 11 (14%) | 6 (8%) | 5 (6%) | 0.7348 |
| MD | 4 (5%) | 4 (5%) | 0 (0%) | |
| Stage | ||||
| IA/IB | 46 (59%) | 29 (37%) | 17 (22%) | |
| IIA/IIB | 14 (18%) | 8 (10%) | 6 (8%) | |
| IIIA/IIIB | 18 (23%) | 14 (18%) | 4 (5%) | 0.4162 |
| Tumour status | ||||
| T1–2 | 68 (87%) | 42 (54%) | 26 (33%) | |
| T3–4 | 10 (13%) | 9 (12%) | 1 (1%) | 0.0797 |
| Nodal status | ||||
| N0 | 53 (68%) | 35 (45%) | 18 (23%) | |
| N1–3 | 25 (32%) | 16 (21%) | 9 (12%) | 0.8599 |
| Lymphatic invasion | ||||
| Negative | 35 (45%) | 26 (33%) | 9 (12%) | |
| Positive | 42 (54%) | 24 (31%) | 18 (23%) | 0.1165 |
| MD | 1 (1%) | 1 (1%) | 0 (0%) | |
| Venous invasion | ||||
| Negative | 45 (58%) | 30 (38%) | 15 (19%) | |
| Positive | 32 (41%) | 20 (26%) | 12 (15%) | 0.7057 |
| MD | 1 (1%) | 1 (1%) | 0 (0%) | |
| Adjuvant chemotherapy | ||||
| Yes | 33 (42%) | 20 (26%) | 13 (17%) | |
| No | 45 (58%) | 31 (40%) | 14 (18%) | 0.4475 |
Data are median (range) or number (%) unless otherwise stated.
EGFR, epidermal growth factor receptor; MD, missing data; NSCLC, non-small cell lung cancer.